5DT.F ENTERA BIO IS-0000769
- Market cap
- EUR 488M
- P/E
- -
- P/B
- 75.21x
- ROE
- -297.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 5DT.F undervalued?
Graham numberThe Graham number of ENTERA BIO IS-0000769 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ENTERA BIO IS-0000769 fundamental analysis
No fundamental analysis for ENTERA BIO IS-0000769 yet.
ENTERA BIO IS-0000769 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ENTERA BIO IS-0000769
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the tre…
Full company profileENTERA BIO IS-0000769 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ENTERA BIO IS-0000769 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 571K | 134K | 0.00 | 181K | 42.0K | 0.00 |
| Gross Profit | 198K | 33.0K | 0.00 | 9.00K | 0.00 | 0.00 |
| Operating Income | -12.2M | -13.0M | -8.89M | -9.59M | -11.5M | -16.2M |
| EBITDA | - | -13.0M | -8.84M | -9.54M | -11.5M | -16.2M |
| Net Income | -12.2M | -13.1M | -8.89M | -9.54M | -11.4M | -21.6M |
| EPS | -0.42 | -0.45 | -0.25 | -0.25 | -0.25 | -0.44 |
| Balance Sheet | ||||||
| Total Assets | 26.0M | 13.1M | 11.8M | 9.39M | 16.0M | 19.5M |
| Total Liabilities | 3.42M | 1.37M | 1.38M | 1.31M | 2.89M | 12.2M |
| Shareholders' Equity | 22.6M | 11.8M | 10.4M | 8.08M | 13.1M | 7.27M |
| Cash & Short-term Investments | 24.9M | 12.3M | 11.0M | 8.66M | 7.11M | 11.3M |
| Cash Flow | ||||||
| Operating Cash Flow | -9.06M | -12.5M | -7.31M | -6.82M | -7.37M | -13.1M |
| Capital Expenditure | 17.0K | 47.0K | 17.0K | 3.00K | 107K | 0.00 |
| Free Cash Flow | -9.08M | -12.5M | -7.33M | -6.82M | -7.48M | -13.1M |
| Ratios | ||||||
| ROE | -54.0% | -111.2% | -85.6% | -118.1% | -87.3% | -297.7% |
| ROA | -46.9% | -99.6% | -75.6% | -101.6% | -71.5% | -111.1% |
| Net Profit Margin | -2,134.3% | -9,754.5% | - | -5,271.3% | -27,235.7% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ENTERA BIO IS-0000769 dividends
ENTERA BIO IS-0000769 has not paid dividends in the last 5 fiscal years.
Who owns ENTERA BIO IS-0000769
- Insiders 5.43%
- Institutions 39.27%
- Public & others 55.31%
- Shares outstanding 174M
- Free float 118M
ENTERA BIO IS-0000769 company profile
- Company name
- ENTERA BIO IS-0000769
- Ticker
- 5DT.F
- ISIN
- IL0011429839
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 20
- Fiscal year end
- December
- Address
- Kiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002
- Phone
- 972 2 532 7151
- Website
- enterabio.com
About ENTERA BIO IS-0000769
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
ENTERA BIO IS-0000769 management
9- Ms. Miranda J. Toledano M.B.A.CEO & Director · born 1977
- Dr. Hillel Galitzer M.B.A., Ph.D.Chief Operating Officer · born 1978
- Dr. Gregory Burshtein Ph.D.Chief of Research & Development · born 1976
- Ms. Dana Yaacov-Garbeli CPAChief Financial Officer · born 1983
- Dr. Rachel B. WagmanChief Clinical Advisor
- Ms. Cherin SmithExecutive VP & Head of Clinical Operations
- Dr. Constantin Itin Ph.D., R.Ph.Head of Biopharmaceutics & Bioanalytics
- Ms. Michele McDermottMD & EVP of Medical Affairs
- Mr. Riccardo Paolo Camisasca M.D.Chief Medical Officer